ISLAND PHARMACEUTICALS LIMITED (ILA)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ILA

ILA - ISLAND PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.38

25 Jun
2026

-0.010

OPEN

$0.41

-2.56%

HIGH

$0.43

389,679

LOW

$0.38

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 20222023202420252026
EPS Basic xxxxxxxxxxxx-3.6
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxx4.5
Net Operating Cash Flow xxxxxxxxxxxx-4.8 M
Net Profit Margin xxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20222023202420252026
Return on Capital Employed xxxxxxxxxxxx-95.50 %
Return on Invested Capital xxxxxxxxxxxx-95.50 %
Return on Assets xxxxxxxxxxxx-91.62 %
Return on Equity xxxxxxxxxxxx-95.50 %
Return on Total Capital xxxxxxxxxxxx-103.01 %
Free Cash Flow ex dividends xxxxxxxxxxxx-4.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20222023202420252026
Short-Term Debt xxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx13 M
Price To Book Value xxxxxxxxxxxx8.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20222023202420252026
Capex xxxxxxxxxxxx0.8 M
Capex % of Sales xxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxx3 M
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Research as a Service (RaaS)

18/06/2026

-1

No Rating

-2.56%

Island Pharmaceuticals has announced GMP manufacturing for Galidesivir has commenced via PI Health Sciences.

Existing inventory is available for the upcoming dose optimisation study, while this agreement and GMP supply establishes manufacturing, analytical and quality systems required for future regulatory and procurement activities.

The company has also announced expansion of its existing cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation.

This amendment has confirmed the planned dose optimisation study that is expected to commence in the September quarter. Research as a Service (RaaS) retains a valuation at $1.24.

Research as a Service (RaaS) research doesn't carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.

FORECAST
Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.77 cents.
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of 101.06 cents.
Access Extra Coverage Research History >

ILA STOCK CHART

FNArena News on ILA

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest